Hologic — May 2, 2024 release

      Current Guidance*   Previous Guidance         Guidance $   Reported % Increase (Decrease) Constant Currency % Increase (Decrease) Organic excluding COVID-19 % Increase   Guidance $   Fiscal 2024                     Revenue     $4,000 - $4,050   (0.8%) to 0.5% (0.8%) to 0.4% 5.1% to 6.5%   $3,990-$4,065   GAAP EPS     $3.45 - $3.55   88.5% to 94.0%        $3.52-$3.67   Non-GAAP EPS     $4.02 - $4.12   1.5% to 4.0%        $3.97-$4.12                         Q3 2024                     Revenue     $992.5 - $1,007.5   0.8% to 2.4% 1.2% to 2.7% 4.0% to 5.6%       GAAP EPS     $0.80 - $0.87   600.0% to 643.8%           Non-GAAP EPS     $0.98 - $1.05   5.4% to 12.9%           *Fiscal 2024 has four fewer selling days compared to fiscal 2023.  Factored into our guidance, we estimate the impact of the four fewer selling days to be a headwind of more than 100 bps for the full year.  Previously provided fiscal year revenue guidance midpoint of $4,027.5 million ($4,015.5 million in constant currency), compared to current revenue guidance midpoint of $4,025 million ($4,022 million in constant currency). Use of Non-GAAP Financial Measures The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; organic revenues excluding COVID-19, non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net margin; non-GAAP EPS; adjusted EBITDA; adjusted net leverage ratio and adjusted ROIC. Organic revenue for the fiscal second quar